Several
guanosine analogues, i.e.
acyclovir (and its oral
prodrug valaciclovir),
penciclovir (in its oral
prodrug form,
famciclovir) and
ganciclovir, are widely used for the treatment of herpesvirus [i.e. herpes simplex virus type 1 (HSV-1), and type 2 (HSV-2), varicella-zoster virus (VZV) and/or human cytomegalovirus (HCMV)]
infections. In recent years, several new
guanosine analogues have been developed, including the 3-membered cyclopropylmethyl and -methenyl derivatives (A-5021 and
synguanol) and the 6-membered D- and L-cyclohexenyl derivatives. The activity of the acyclic/carbocyclic
guanosine analogues has been determined against a wide spectrum of viruses, including the HSV-1, HSV-2, VZV, HCMV, and also human herpesviruses type 6 (HHV-6), type 7 (HHV-7) and type 8 (HHV-8), and hepatitis B virus (HBV). The new
guanosine analogues (i.e. A-5021 and D- and
L-cyclohexenyl G) were found to be particularly active against those viruses (HSV-1, HSV-2, VZV) that encode for a specific
thymidine kinase (TK), suggesting that their
antiviral activity (at least partially) depends on phosphorylation by the virus-induced TK. Marked
antiviral activity was also noted with
A-5021 against HHV-6 and with D- and
L-cyclohexenyl G against HCMV and HBV. The
antiviral activity of the acyclic/carbocyclic
nucleoside analogues could be markedly potentiated by
mycophenolic acid, a potent inhibitor of
inosine 5'-monophosphate (
IMP) dehydrogenase. The new carbocyclic
guanosine analogues (i.e. A-5021 and D- and
L-cyclohexenyl G) hold great promise, not only as
antiviral agents for the treatment of
herpesvirus infections, but also an
antitumor agents for the combined gene therapy/
chemotherapy of
cancer, provided that (part of) the
tumor cells have been transduced by the viral (HSV-1, VZV) TK gene.